ArticleNews reportPHN-05422026-11-01 23:08 CT

Eli Lilly tops $1 trillion as Novo Nordisk eats the losses of a drug war

Source · Startup Fortune

TLDR

Startup Fortune reports that Eli Lilly’s market value reached about $1.26 trillion after its tirzepatide drugs generated more than $16 billion in third-quarter sales. Rival Novo Nordisk approaches its November 4 earnings report after warning that 2026 sales and operating profit could decline 5–13%.

01—Key points

01The article reports Lilly’s quarterly revenue rose 39% to $24.4 billion, with Mounjaro and Zepbound sales totaling $16.07 billion.
02Lilly raised its full-year 2026 revenue guidance to $91–92 billion, according to the report.
03Novo cited pricing pressure, insurer rebate demands and semaglutide patent expirations in some markets outside the United States.

Why it matters Editorial

The report highlights divergent commercial performance among major diabetes and obesity drugmakers despite demand for obesity treatments.

Read the original at Startup Fortune↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.